Literature DB >> 27806870

Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).

Mar Guasp1, Nuria Solà-Valls1, Eugenia Martínez-Hernández2, M Pilar Gil3, Cristina González3, Luis Brieva3, Albert Saiz4, Josep Dalmau5, Francesc Graus4, Helena Ariño6.   

Abstract

Cerebellar ataxia is one of the most frequent syndromes associated with autoantibodies against glutamic acid decarboxylase (GAD-ab). Antibodies recognize the isoform GAD65, which is the standard biomarker, but additional immunoreactivity against GAD67 is found in high proportion of patients with GAD-ab-associated neurological disorders. We describe the case of a 59-year-old woman who presented with pancerebellar syndrome of subacute onset (9weeks to nadir). In the etiological study, high titers of GAD-ab were found, but these only recognized the GAD67 isoform and not the GAD65. Screening of GAD67-ab should be considered in late-onset cerebellar ataxia when GAD65-ab are absent.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27806870      PMCID: PMC5831398          DOI: 10.1016/j.jneuroim.2016.09.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases.

Authors:  H M Meinck; L Faber; N Morgenthaler; J Seissler; S Maile; M Butler; M Solimena; P DeCamilli; W A Scherbaum
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-07       Impact factor: 10.154

2.  Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome.

Authors:  S Jarius; O Stich; J Speck; Ch Rasiah; B Wildemann; H M Meinck; S Rauer
Journal:  J Neuroimmunol       Date:  2010-09-01       Impact factor: 3.478

3.  International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.

Authors:  P Trouillas; T Takayanagi; M Hallett; R D Currier; S H Subramony; K Wessel; A Bryer; H C Diener; S Massaquoi; C M Gomez; P Coutinho; M Ben Hamida; G Campanella; A Filla; L Schut; D Timann; J Honnorat; N Nighoghossian; B Manyam
Journal:  J Neurol Sci       Date:  1997-02-12       Impact factor: 3.181

4.  Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.

Authors:  J Honnorat; A Saiz; B Giometto; A Vincent; L Brieva; C de Andres; J Maestre; N Fabien; A Vighetto; R Casamitjana; C Thivolet; B Tavolato; J Antoine; P Trouillas; F Graus
Journal:  Arch Neurol       Date:  2001-02

5.  Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity.

Authors:  A Saiz; J Arpa; A Sagasta; R Casamitjana; J J Zarranz; E Tolosa; F Graus
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

Review 6.  A critical update on the immunopathogenesis of Stiff Person Syndrome.

Authors:  Harry Alexopoulos; Marinos C Dalakas
Journal:  Eur J Clin Invest       Date:  2010-08-19       Impact factor: 4.686

7.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Direct evidence for limited clonality of antibodies to glutamic acid decarboxylase (GAD) in stiff man syndrome using baculovirus expressed GAD.

Authors:  A P Johnstone; S S Nussey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

9.  Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.

Authors:  Albert Saiz; Yolanda Blanco; Lidia Sabater; Félix González; Luis Bataller; Roser Casamitjana; Lluis Ramió-Torrentà; Francesc Graus
Journal:  Brain       Date:  2008-08-07       Impact factor: 13.501

10.  Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity.

Authors:  Nuria Gresa-Arribas; Helena Ariño; Eugenia Martínez-Hernández; Mar Petit-Pedrol; Lidia Sabater; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  10 in total
  6 in total

Review 1.  Autoantibody Encephalitis: Presentation, Diagnosis, and Management.

Authors:  Eric Lancaster
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

Review 2.  Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses.

Authors:  Sergio Muñiz-Castrillo; Alberto Vogrig; Nicolás Lundahl Ciano-Petersen; Macarena Villagrán-García; Bastien Joubert; Jérôme Honnorat
Journal:  Cerebellum       Date:  2022-01-12       Impact factor: 3.648

Review 3.  Treatment of Cerebellar Ataxia in the Context of Systemic Diseases.

Authors:  Malcolm Proudfoot; Alastair Wilkins
Journal:  Curr Treat Options Neurol       Date:  2017-11-25       Impact factor: 3.598

Review 4.  Hello from the Other Side: How Autoantibodies Circumvent the Blood-Brain Barrier in Autoimmune Encephalitis.

Authors:  Maryann P Platt; Dritan Agalliu; Tyler Cutforth
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

Review 5.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

Review 6.  Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis.

Authors:  Gerda Ricken; Carmen Schwaiger; Desiree De Simoni; Valerie Pichler; Julia Lang; Sarah Glatter; Stefan Macher; Paulus S Rommer; Petra Scholze; Helmut Kubista; Inga Koneczny; Romana Höftberger
Journal:  Front Neurol       Date:  2018-10-10       Impact factor: 4.086

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.